Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
February 21 2023 - 4:05PM
Business Wire
Conference Call Scheduled for Tuesday, February
28, 2023 at 4:30 p.m. ET.
Revance Therapeutics, Inc. (RVNC), today announced that the
company will release fourth quarter and full year 2022 financial
results on Tuesday, February 28, 2023, after the close of market.
Revance will host a corresponding conference call and a live
webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss
the results and provide a corporate update.
Individuals interested in listening to the conference call may
do so by dialing (800) 715-9871 and reference conference ID:
1286316, or from the webcast link in the investor relations section
of the company's website at: www.revance.com.
A replay of the call will be available beginning February 28,
2023, at 4.30 p.m. PT / 7.30 p.m. ET to March 28, 2023 at 4.30 p.m.
PT / 7.30 p.m. ET. To access the replay, dial (800) 770-2030 and
reference conference ID: 1286316. The webcast will be available in
the investor relations section on the company's website for 90 days
following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
elevate patient and physician experiences. Revance’s aesthetics
portfolio of expertly created products and services, including
DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA®
Collection of dermal fillers, and OPUL®, the first-of-its-kind
Relational Commerce platform for aesthetic practices, deliver a
differentiated and exclusive offering for the company’s elite
practice partners and their consumers. Revance has also partnered
with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for
injection, which will compete in the existing short-acting
neuromodulator marketplace. Revance’s therapeutics pipeline is
currently focused on muscle movement disorders including evaluating
DAXXIFY® in two debilitating conditions, cervical dystonia and
upper limb spasticity.
Revance is headquartered in Nashville, Tennessee, with
additional office locations in Newark, Pleasanton and Irvine,
California. Learn more at www.Revance.com,
www.RevanceAesthetics.com, DAXXIFY.RevanceAesthetics.com, or
connect with us on LinkedIn.
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are
registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE
SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230221005804/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara J. Fahy,
949-887-4476 sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024